Post Profile

Abnormal Brain Protein May Contribute to Alzheimer's Disease Development

A recently-recognized pathologic protein in the brain may play a larger role in the development of clinical Alzheimer's disease dementia than previously recognized, according to a study by researchers at Rush University Medical Center. The findings of the study of nearly 1,000 older adults were published in the Sept. 30 issue of the journal, Brain.
read more


Related Posts

Study: Alzheimer’s pathology might be transmissible via medical procedures

Health : The Checkup

A new study suggests that the precursor of an abnormal protein that triggers Alzheimer’s disease could perhaps be transmitted from person to person through the transfer of tissue or certain specialized medical or surgical procedures...

Researchers Gain Better Understanding of the Mechanism Behind Tau Spreading in the Brain and the Progression of Alzheimer's Disease

Health : Newswise Medical News

Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer's disease (AD) and other neurodegenerative disorders. ...

Abnormal Brain Pathology Likely Culprit For Family History Of Alzheimer's Disease

Health : Medical News Today

Close family members of people with Alzheimer's disease are more than twice as likely as those without a family history to develop silent buildup of brain plaques associated with Alzheimer's disease, according to researchers at Duke...

Aberrant Tau proteins put neuronal networks to sleep

Academics / Chemistry : EurekAlert: Chemistry

(DZNE - German Center for Neurodegenerative Diseases) In a study published in the journal PNAS scientists of the German Center for Neurodegenerative Diseases present new findings on the role of the protein Tau in certain brain disea...

Researchers Study Mitochondrial Function, Potential New Therapeutic Target for Alzheimer's Disease

Health : Newswise Medical News

Researchers at Rush University Medical Center are conducting an early phase clinical trial of a novel drug therapy for patients with dementia due to Alzheimer's disease. The drug is a new compound called MSDC-0160, which is an insul...


Copyright © 2016 Regator, LLC